Physician profile
Chloe A Payne
NPI 1083054928
$6,322.77
in general payments reported to CMS, 2019-2025
33 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.53 · 2021: $832 · 2022: $1,180 · 2023: $1,738 · 2024: $1,089 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,996 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.14 |
| Education | $215.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,587.94 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $704.22 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $517.60 | 2021-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $517.29 | 2021-2025 | |
| Lilly USA, LLC | $374.37 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $269.46 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $257.23 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Ucb, INC. | $235.53 | 2021-2025 | Bimzelx |
| Incyte Corporation | $213.32 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $185.70 | 2021-2025 | |
| Pfizer INC. | $166.68 | 2021-2025 | |
| Amgen INC. | $166.09 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $130.51 | 2022-2025 | Arazlo, Jublia, Cabtreo |
| Organogenesis INC. | $122.54 | 2023-2025 | Puraply, Affinity |
| Organon LLC | $105.38 | 2025 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $105.19 | 2019-2025 | Aklief, Epsolay, Oracea |
| Journey Medical Corporation | $91.49 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $86.30 | 2023-2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.48 | 2022-2024 | Sotyktu |
| Akebia Therapeutics INC | $64.12 | 2019 | |
| Biofrontera INC. | $44.20 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.87 | 2024 | Spevigo |
| Strata Skin Sciences, INC. | $30.56 | 2024 | Xtrac |
| Cipher Pharmaceuticals US LLC | $30.30 | 2025 | Natroba, Spinosad |
| Genentech USA, INC. | $27.18 | 2024 | Erivedge |
| Botanix Sb INC | $22.83 | 2025 | Sofdra |
| Nabriva Therapeutics, Plc | $18.27 | 2021 | |
| Lnhc, INC | $17.86 | 2025 | Zelsuvmi |
| Almirall LLC | $17.83 | 2022 | |
| Merz North America, INC. | $17.28 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.27 | 2024 | Ycanth |
| Leo Pharma INC. | $15.89 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.